Bachem Holding
From Wikipedia, the free encyclopedia
 | |
 Offices in Bubendorf, Switzerland | |
| Company type | Stock company |
|---|---|
| SIX: BANB | |
| ISIN | CH0012530207 |
| Industry | Chemicals, biotechnology, pharmaceuticals |
| Founded | 1971 |
| Headquarters | Bubendorf, Switzerland |
| Revenue | CHF 695.1 million[1] (2025) |
Number of employees | 2511[1] |
| Website | bachem |
Bachem Holding AG is a Swiss biotechnology company specializing in the development and manufacture of peptides and complex organic molecules for use as active pharmaceutical ingredients (APIs). The company focuses on peptide-based therapeutics, including large-scale commercial production and process development for pharmaceutical applications. It was founded in 1971 and is a subsidiary of Ingro Finanz AG.[2]
The head office is in Bubendorf in the canton of Basel-Landschaft. Bachem operates production facilities in Vionnaz (Switzerland), Vista and Torrance (United States), and St Helens (United Kingdom), as well as a sales and distribution site in Tokyo.[citation needed]
Bachem is one of the largest manufacturers of peptide-based APIs globally, supplying pharmaceutical and biotechnology companies with products used in both clinical development and commercial therapies.[citation needed]
In recent years, the company has expanded its manufacturing capacity, including new large-scale production facilities in Switzerland and the United States.[1]
At the end of 2025, the company employed 2,511 people, reported revenue of CHF 695.1 million, and net income of CHF 148.8 million.[1]
